MARKET

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ
1.770
-0.130
-6.85%
Opening 14:21 05/20 EDT
OPEN
1.960
PREV CLOSE
1.900
HIGH
1.980
LOW
1.710
VOLUME
116.26K
TURNOVER
0
52 WEEK HIGH
398.40
52 WEEK LOW
1.710
MARKET CAP
3.85M
P/E (TTM)
-0.0397
1D
5D
1M
3M
1Y
5Y
Seelos Therapeutics announces pricing of about $1M registered direct offering & concurrent private placement
Healthcare Seelos Therapeutics announces pricing of about $1M registered direct offering & concurrent private placement May 17, 2024. SEEL expects gross proceeds of approximately $ million from the registered direct sale. The company intends to use the net proceeds from the offering for general corporate purposes.
Seeking Alpha · 3d ago
*Seelos Therapeutics Prices $1.1M Registered Direct Offering, Concurrent Private Placement >SEEL
Dow Jones · 3d ago
*Seelos Therapeutics: Offering, Placement Expected to Close Around May 21 >SEEL
Dow Jones · 3d ago
SEELOS THERAPEUTICS ANNOUNCES PRICING OF $1.1 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 3d ago
GoodRx Holdings, Seelos Therapeutics, Clever Leaves among healthcare movers
Healthcare On the Move: GoodRx Holdings, Seelos Therapeutics, Clever Leaves among healthcare movers. S&P 500 Health Care Sector contributes 58% to index. Health Care Equipment & Services and Services are among the top three sectors in the index.
Seeking Alpha · 4d ago
SEEL Stock Earnings: Seelos Therapeutics Beats EPS, Beats Revenue for Q1 2024
Seelos Therapeutics just reported results for the first quarter of 2024. The company reported earnings per share of -20 cents. Seelos reported revenue of $579,000. This was 93% better than the analyst estimate for revenue of -50 million.
Investorplace · 6d ago
Seelos Therapeutics Announces Common Stock Reverse Split
TipRanks · 6d ago
Seelos Therapeutics Approves 1-For-8 Reverse Stock Split, To Begin Trading On A Reverse Stock Split-Adjusted Basis At The Opening Of The Market On Thursday, May 16, 2024
Seelos Therapeutics, Inc. Is a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases. The Company's Board of Directors approved a 1-for-8 reverse stock split of its outstanding shares of common stock to be effective on May 16, 2024. The company's common stock will continue to trade on the Nasdaq Capital Market.
Benzinga · 6d ago
More
About SEEL
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

Webull offers Seelos Therapeutics Inc stock information, including NASDAQ: SEEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SEEL stock methods without spending real money on the virtual paper trading platform.